Polysaccharide of Atractylodis Macrocephalae Rhizoma inhibits expression of immune checkpoint PD-L1 by targeting miR-34a in esophageal carcinoma cells.
10.19540/j.cnki.cjcmm.20211203.701
- Author:
Yi-Cun HAN
1
;
Yu-Long CHEN
2
;
Xiu-Qi FAN
3
;
Yi-Wan SHANG
1
;
Xing CHEN
1
;
Ge WANG
3
;
Bian SHI
3
;
Qi-Long GAO
3
Author Information
1. Graduate School, Henan University of Chinese Medicine Zhengzhou 450046, China.
2. Academy of Chinese Medicine, Henan University of Chinese Medicine Zhengzhou 450046, China.
3. the Affiliated Tumor Hospital, Zhengzhou University Zhengzhou 450008, China.
- Publication Type:Journal Article
- Keywords:
PD-L1;
esophageal carcinoma;
miR-34a;
polysaccharide of Atractylodis Macrocephalae Rhizoma(PAMR)
- MeSH:
B7-H1 Antigen/pharmacology*;
Carcinoma;
Cell Proliferation;
Humans;
MicroRNAs/metabolism*;
Polysaccharides/pharmacology*
- From:
China Journal of Chinese Materia Medica
2022;47(6):1658-1665
- CountryChina
- Language:Chinese
-
Abstract:
The immune checkpoint programmed cell death-ligand 1(PD-L1)-mediated immunosuppression is among the important features of tumor. PD-L1, an immunosuppressant, can induce T cell failure by binding to programmed cell death-1(PD-1). Thus, the key to restoring the function of T cells is inhibiting the expression of PD-L1. The Chinese medicinal Atractylodis Macrocephalae Rhizoma(AMR) has the anti-tumor, anti-inflammatory, antioxidant, and hypoglycemic activities, and the polysaccharide in AMR(PAMR) plays a crucial role in immunoregulation, but the influence on the immune checkpoints which are closely related to immunosuppression has not been reported. MicroRNA-34 a(miR-34 a) expression in esophageal carcinoma tissue is significantly lower than that in normal tissue. This study aims to investigate the inhibitory effect of PAMR on esophageal carcinoma cells, and the relationship between its inhibitory effect on PD-L1 expression and miR-34 a, which is expected to clarify the anti-tumor mechanism of PAMR. Firstly, different human esophageal carcinoma cell lines(EC9706, EC-1, TE-1, EC109 cells) were screend out, and expression of PD-L1 was determined. Then, EC109 cells, with high expression of PD-L1, were selected for further experiment. The result showed that PAMR suppressed EC109 cell growth. According to the real-time quantitative PCR(qPCR) and Western blot, it significantly suppressed the mRNA and protein expression of PD-L1, while promoting the expression of tumor suppressor miR-34 a. The confocal microscopy and luci-ferase assay proved that PAMR alleviated the inhibitory effect of PD-L1 while blocked miR-34 a. Additionally, the expression of PD-L1 was controlled by miR-34 a, and the combination of miR-34 a inhibitor with high-dose PAMR reversed the inhibitory effect of PAMR on PD-L1 protein expression. Thus, the PAMR may inhibit PD-L1 by increasing the expression of miR-34 a and regulating its downstream target genes. In conclusion, PAMR inhibits the expression of PD-L1 mainly by inducing miR-34 a.
